- Clinical Trials
- April 2024
- 40 Pages
Global
From €1201EUR$1,250USD£1,027GBP
- Drug Pipelines
- January 2019
- 60 Pages
Global
From €1922EUR$2,000USD£1,643GBP
- Report
- January 2022
- 200 Pages
Global
From €7206EUR$7,500USD£6,161GBP
- Report
- January 2022
- 60 Pages
Global
From €3795EUR$3,950USD£3,245GBP
- Report
- August 2022
- 120 Pages
Global
From €4324EUR$4,500USD£3,697GBP
- Report
- April 2022
- 199 Pages
Global
From €4804EUR$5,000USD£4,107GBP
- Clinical Trials
- September 2019
- 159 Pages
Global
From €2402EUR$2,500USD£2,054GBP
- Drug Pipelines
- July 2020
- 75 Pages
Global
From €1922EUR$2,000USD£1,643GBP
- Report
- November 2023
- 91 Pages
Global
From €3500EUR$3,902USD£3,097GBP
- Drug Pipelines
- March 2021
Global
From €1922EUR$2,000USD£1,643GBP
- Report
- March 2024
- 132 Pages
Global
From €913EUR$950USD£780GBP
Bacterial Vaginosis (BV) is a common vaginal infection caused by an imbalance of bacteria in the vagina. BV is typically treated with antibiotics, such as metronidazole, clindamycin, and tinidazole. These antibiotics are part of the Infectious Diseases Drugs market, which includes drugs used to treat a variety of bacterial, viral, and fungal infections.
The Bacterial Vaginosis Drug market is a subset of the Infectious Diseases Drugs market, and is composed of antibiotics used to treat BV. These drugs are typically prescribed in the form of oral tablets, topical creams, and vaginal gels.
Some companies in the Bacterial Vaginosis Drug market include Pfizer, Merck, GlaxoSmithKline, and Bayer. Show Less Read more
